Extensively drug–resistant (XDR) and pre-XDR- tuberculosis (TB) account for approximately a third of pediatric MDR–TB cases globally. Clinical management is challenging; recommendations are based on l
Background Oral multikinase inhibitors and immune checkpoint inhibitors (ICIs) are effective for treating advanced hepatocellular carcinoma (aHCC) but may increase cost. This study compared the cost-e
BackgroundOral multikinase inhibitors and immune checkpoint inhibitors (ICIs) are effective for treating advanced hepatocellular carcinoma (aHCC) but may increase cost. This study compared the cost-ef
Extensively drug–resistant (XDR) and pre-XDR- tuberculosis (TB) account for approximately a third of pediatric MDR–TB cases globally. Clinical management is challenging; recommendations are based on l